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Summary 
OBJECTIVE: To evaluate contrast-enhanced magnetic 
resonance angiography (MRA) in diagnosis of in-
flammatory aortic involvement in patients with clinical 
suspicion of large-vessel vasculitis. 
PATIENTS AND METHODS: Seventy-five patients, 
mean age 62 years (range 16–82 years), 44 female and 
31 male, underwent gadolinium-enhanced MRA and 
were evaluated retrospectively. Thoracic MRA was 
performed in 32 patients, abdominal MRA in 7 pa-
tients and both thoracic and abdominal MRA in 36 
patients. Temporal arterial biopsies were obtained 
from 22/75 patients. MRA positivity was defined as 
increased aortic wall signal in late gadolinium-
enhanced axial turbo inversion recovery magnitude 
(TIRM) series. The influence of prior glucocorticoid 
intake on MRA outcome was evaluated. 
RESULTS: MRA was positive in 24/75 patients, with 
lesions located in the thorax in 7 patients, the abdo-
men in 5 and in both thorax and abdomen in 12. Prob-
ability for positive MRA after glucocorticoid intake for 
more than 5 days before MRA was reduced by 89.3%. 
Histology was negative in 3/10 MRA-positive patients 
and positive in 5/12 MRA-negative patients. All 5/12 
histology positive / MRA-negative patients had gluco-
corticoids for >5 days prior to MRA and were diag-
nosed as having vasculitis. Positive predictive value 
for MRA was 92%, negative predictive value was 88%. 
CONCLUSIONS: Contrast-enhanced MRA reliably 
identifies large vessel vasculitis. Vasculitic signals in 
MRA are very sensitive to glucocorticoids, suggesting 
that MRA should be done before glucocorticoid treat-
ment. 
Key words: magnetic resonance angiography; sys-
temic vasculitis; diagnostic imaging; glucocorticoids; 
predictive value of tests 
Introduction 
Giant-cell arteritis represents the most common form of 
large vessel vasculitis in people over the age of 50 years. 
Giant cell arteritis can affect either the cranial arteries, the 
thoracoabdominal aorta (large-vessel giant-cell arteritis), or 
both [1]. Data on annual incidences report 6 to 32 cases per 
100 000 people worldwide [2, 3]. Cranial giant-cell arteritis, 
also called temporal arteritis, typically presents with ma-
laise, temporal headache and claudication of the masseter 
muscle, as well as visual impairment and serological signs of 
systemic inflammation (erythrocyte sedimentation rates [ 
ESR] >50 mm within the first hour and/or elevated values 
for C-reactive protein [CRP]). Polymyalgic symptoms often 
precede or accompany giant-cell arteritis. Cranial giant-cell 
arteritis is present in approximately 20% of classical cases of 
polymyalgia rheumatica. 
The vasculitis counterpart in patients younger than 45 years 
of age is called Takayasu arteritis. This form of large-vessel 
vasculitis typically affects branches of the aortic arch. As a 
consequence, patients present with claudication of the 
upper limbs accompanied by pulselessness and differences 
in blood pressure between the two arms. 
It is important to note that these summarised symptoms 
may be absent in large vessel vasculitis. Therefore, large-
vessel vasculitis is an important differential diagnosis in 
systemic inflammatory response syndrome (SIRS) of un-
known origin. The established classification criteria of the 
American College of Rheumatology (ACR) will fail in such 
cases, in long-standing disease or after premedication with 
immunosuppressants [4, 5]. 
Temporal artery biopsy is still regarded as gold standard. Of 
note, segmental vasculitis can be missed if resected arteries 
are too short or if biopsies are not meticulously analysed. 
Colour-coded ultrasound of extracranial arteries yields good 
specificity and sensitivity when compared with fluorode-
oxy-glucose positron emission tomography (FDG-PET) [6], 
Even so, large vessel inflammation can be missed owing to 
technical limitations of ultrasound transducer devices [7]. 
Other imaging techniques, such as contrast-guided comput-
ed tomography angiography (CTA), have shown good results 
but carry the risk of contrast and radiation exposure, and 
might miss early inflammation [8]. PET, despite being cost-
intensive, is regarded as an upcoming option, but is as yet 
neither routinely nor immediately available [9]. 
Contrast-enhanced magnetic resonance imaging of arteries 
(MRA) can demonstrate early inflammation of vessel walls. 
An excellent performance in diagnosing temporal artery 
vasculitis was recently shown [10]. Additionally, MRA pro-
vides structural information, for example regarding differ-
ential diagnoses. So far, however, MRA for diagnosing thora-
coabdominal aortitis has been reported in a few patients 
only [11]. Preceding immunosuppression, mostly consisting 
of glucocorticoids, can not only suppress clinical symptoms 
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but also reduce the possibility to detect inflammatory sig-
nals in diagnostic tests [12, 13]. 
The objective of our study was to define the diagnostic value 
of contrast-enhanced MRA in patients with clinical suspi-
cion of large-vessel vasculitis at our university centre and to 
define the impact of glucocorticoid treatment on inflamma-
tory signals. 
Patients and methods 
The radiological database was searched for patients referred 
for MRA with the clinical suspicion of large-vessel vasculitis. 
Patients with an incidental finding of large-vessel vasculitis 
on MRA were excluded. Patients were referred for MRA if the 
case history and/or clinical and serological work-up could 
not clearly identify or rule out any form of underlying large-
vessel vasculitis. All referrals were matched with clinical 
records to yield this cohort. ESR and CRP values at the time 
of MRA, prior and/or current glucocorticoid medication, and 
histology of temporal artery biopsies were retrieved. Our 
standard of care is bitemporal arterial biopsies [14]. 
Clinical diagnosis was regarded as the gold standard, and 
was established by consultant rheumatologists with long-
standing experience (SA, FW, PV). MRA was evaluated by the 
radiologist who initiated the protocol (HB) and inde-
pendently by a second MRI-specialised radiologist (TK). Both 
radiologists had experience in the routine clinical assess-
ment of vascular disease for more than 10 years, and had 
worked on the same team for 2 years. 
As all radiological evaluations were part of a routine diag-
nostic work-up, patients’ consent for data evaluation was 
not needed. At the time of study conception, retrospective 
analyses of routine data were not bound to be judged by the 
local ethics committee. 
MRA protocol and evaluation 
All examinations were performed using an advanced 3 Tesla 
MR Scanner (Skyra, Siemens, Erlangen, Germany). The pro-
tocol included coronal fat suppressed T2 half-fourier acqui-
sition single-shot turbo sequence (HASTE), axial T2 fast low 
angle shot (FLASH) axial true fast imaging with steady state 
precession (TRUFISP), axial turbo inversion recovery magni-
tude (TIRM) in pre-contrast and axial 2D FLASH and volume 
interpolated breathhold examination (VIBE) sequences in 
post MRA series. MRA images were presented in source and 
subtraction images and multiplanar reconstruction (MPR) 
and maximum intensity projection (MIP) reconstructions. 
All patients received Dotarem® (gadoteric acid) as intrave-
nous contrast medium. Additional late series 4 to 5 minutes 
after contrast were taken to present prominently arterial 
wall enhancement. Vessel wall contrast enhancement was 
evaluated in congruence with data from cerebral vasculitis 
[11]. Aortic wall thickness was evaluated to define atheroscle-
rosis as described elsewhere [15]. 
MRAs were evaluated by TK and HB, who were unaware of 
the laboratory parameters and diagnosis, in independent 
reading sessions. Image quality suitable for reporting was 
decided separately by each reader. Concomitant arterial wall 
pathologies obscuring large-vessel vasculitis, such as dissec-
tion, were excluded. MRA positivity was defined as an in-
creased signal in late gadolinium-enhanced series within the 
aortic wall detected on axial TIRM imaging showing intra-
mural oedema [16, 17]. Wall oedema itself and/or extralu-
minal aortic soft tissue enlargement were not counted as 
large-vessel vasculitis as such. 
Wall thickness and stenosis were evaluated in a search for 
atherosclerosis. To distinguish atherosclerotic findings, 
typical MR features of atherosclerosis were also focused on 
and evaluated for all patients [18]. Finally, radiological diag-
nostic confidence in the diagnosis of vasculitis was rated for 
all patients. MRA examples are given in figure 1.  
 
 
 
 
Figure 1: Examples of 
negative and positive 
magnetic resonance 
angiography (MRA) 
findings in the thorax 
and abdomen, each T-1 
weighted images 10 
minutes after admin-
istration of gadolinium-
containing contrast 
medium. (A) Thoracic 
MRA without signs of 
vasculitis. (B) Thoracic 
MRA demonstrating 
vasculitis. (C) Ab-
dominal MRA without 
signs of vasculitis, 
arrowhead pointing to 
atherosclerotic plaque. 
(D) Abdominal MRA 
demonstrating vascu-
litis. 
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Statistical evaluation 
Data were presented as descriptive statistics using Stata 
Version 13.1. Chi square and Fisher's exact tests were used for 
sensitivity and specificity analysis. The Mann-Whitney test 
was used for group comparisons as non-normal distribution 
was assumed. A p-value <0.05 was considered statistically 
significant. 
Results 
Between January 2005 and September 2012, we identified 75 
patients (for characteristics see table 1). Seven out of 75 
patients were <50 years old. Of these, one patient was evalu-
ated for Takayasu’s arteritis and the remaining patients had 
suspicion of large-vessel vasculitis of any other kind. All MR 
angiograms were of diagnostic quality. No patient had signs 
of aortic dissection that might have obscured potential signs 
of large-vessel vasculitis. A minor aortic dissection in one 
patient was short and left the major thoracoabdominal part 
unaltered. 
Thoracic MRA only was performed in 32/75 patients, ab-
dominal MRA only in 7/75, and both thoracic and abdominal 
MRA in 36/75. 
Overall, 24/75 (32%) MR angiograms were positive for large-
vessel vasculitis. The manifestations and final diagnoses of 
patients with either negative or positive MRA are shown in 
tables 2 and 3. 
 
 
Table 1: Overview of patient characteristics: laboratory, histological and radiographic parameters. Total n = 75. CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate; GC = Glucocorticoids; MRA = magnetic resonance angiography; n.s. = not significant. 
 
 MRA positive (n = 24) MRA negative (n = 51) Significance 
Age (years), median (range) 65 (18–82) 61 (16–82) n.s. 
Female (%) 60.8 54.2 n.s. 
Laboratory parameters at time of 
MRA 
ESR (mm/h), median (range) 80 (5–120) (2 missing) 19.5 (3–100) (1 missing) p = 0.007 
CRP (mg/l), median (range) 27 (3–218) (1 missing) 9 (3–145) p = 0.0005 
Immunosuppression prior to MRA GC >5 days prior to MRA 2/23 (1%) (1 missing) 29/50 (58%) (1 missing)  
Histology prior to MRA Histology positive 7/10 5/12  
Histology negative 3/10 7/12  
Radiographic parameters of MRA Intramural vessel wall oedema in late 
contrast series 
17/24 (29%) 2/51 (4%)  
Vessel wall thickening 21/24 (88%) 5/51 (1%)  
Extraluminal soft tissue involvement 16/24 (67%) 0/51 (0%)  
Atherosclerosis 17/24 (71%) 25/51 (49%)  
Dissection 1 0  
Stenotic changes 6/24 (25%) 2/51 (4%)  
 
 
Table 2: Final diagnosis in patients with negative MRA. cGCA = cranial giant-cell arteritis; MRA = magnetic resonance angiography; PMR = 
polymyalgia rheumatica. 
 
 Findings Final diagnosis 
 MRA negative (n = 51) 
Histology 
negative (n = 7) 
Histology 
positive (n = 5) 
PMR cGCA Other 
Thoracic only (n = 32) 25 5 1 10 3 12* 
Abdominal only (n = 7) 2 0 0 2 0 0 
Thoracic plus abdominal (n = 36) 24 2 4 10 4 10† 
 
* 1 patient each diagnosed as Sjögren’s syndrome, bronchial carcinoma, undefined vasculopathy, pachymeningitis, spondyloarthritis, chorioretinitis, recurrent 
thrombosis of unknown origin and aortic ectasia.  
† 11 patients diagnosed as inflammatory syndrome of unknown origin, 1 as Behçet’s disease, 1 as unclear cephalgia and 1 as oligoarthritis. 
 
 
Table 3: Final diagnosis in patients with positive MRA. cGCA = cranial giant-cell arteritis; LVV = large-vessel vasculitis; MRA = magnetic reso-
nance angiography; TAK = Takayasu arteritis. 
 
 Findings Final diagnosis 
 MRA positive (n 
= 24) 
Histology 
negative (n 
= 3) 
Histology 
positive (n 
= 7) 
cGCA with 
LVV 
LVV only TAK Retro-
peritoneal 
fibrosis 
Other 
Thoracic only (n = 32) 7 1 2 2 3 0 0 2* 
Abdominal only (n = 7) 5 0 1 1 1 0 3 0 
Thoracic plus abdominal (n = 
36) 
12 2 4 3 6 1 1 1† 
 
* One patient each diagnosed as Behçet’s vasculitis and polyarthritis. † One patient diagnosed as non-Langhans cell histiocytosis. 
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In 6/51 MRA-negative patients receiving glucocorticoids for 
>5 days, we clinically diagnosed vasculitis and treated them 
as such (with 5/6 showing positive histology). 
Sensitivity of MRA for large-vessel vasculitis was 79%, speci-
ficity 96%. The positive predictive value for MRA was 92% 
and the negative predictive value 88%. MRA gave false posi-
tive results in 4% and false negatives in 21% of patients. 
Laboratory test results 
ESR and CRP were significantly higher in patients with posi-
tive MRA than in those with negative MRA: ESR 80 vs 19.5 
mm/h (p = 0.007) and CRP 27 vs 9 mg/l (p = 0.0005). Among 
patients with positive MRA, two had both normal ESR and 
normal CRP, and another two showed normal values for 
either ESR or CRP. 
Histology 
Temporal artery biopsies of 12/51 MRA-negative patients 
were examined histologically, 5/12 being positive and 7/12 
negative. Patients with positive histology were counted as 
having vasculitis despite a negative MRA. For patients with 
positive MRA, 7/10 biopsies showed positive histology and 
3/10 biopsies were classified as negative. 
Radiological characteristics 
The most striking results were the presence or absence of 
intramural vessel wall oedema in late gadolinium-enhanced 
series for MRA-positive compared with MRA-negative pa-
tients (number of patients with vessel wall oedema 17/24 
MRA positive vs 2/51 MRA negative). Patients without in-
tramural vessel wall oedema presented a combination of 
stenosis, wall thickening and enhancement not directly on 
intraluminal sections and not clearly counted as atheroscle-
rosis, and were therefore judged as vasculitis. In the two 
patients classified as MRA negative despite vessel wall oe-
dema, gadolinium enhancement was only marginally de-
tectable, but atherosclerosis clearly prevailed. Vessel wall 
thickening was present in 21/24 MRA-positive versus 5/51 
MRA-negative patients. 
Atherosclerosis was present in 42/75 patients (17/24 MRA-
positive and 25/51 MRA-negative patients 
Extraluminal aortic soft tissue enlargement was detected in 
none of the MRA-negative patients and in 16 of the MRA 
positive patients, being mild in 11, moderate in 3 and severe 
in 2. Aortic dissection was present in 1/24 MRA positive and 
0/51 MRA negative patients. Aortic stenosis was seen in 6/24 
MRA positive and 2/51 MRA negative patients. 
Interobserver agreement was 98.7%. After discussion, con-
sensus was achieved in 100% of cases. 
Concurrent factors / glucocorticoids 
Assuming decreasing sensitivity of MRA after more than 5 
days of glucocorticoid intake, as demonstrated in cranial 
arteritis patients, we differentiated between glucocorticoid 
intake for either more or less than 5 days [10]. Glucocorti-
coids >5 days prior to MRA were given to 32/75 patients 
(unknown in 2), with significantly more glucocorticoid 
patients in the MRA-negative group (29/50 patients, 1 miss-
ing) than in MRA-positive patients (3/23, 1 missing). 
The probability of positive MRA after glucocorticoid intake 
for more than 5 days before MRA was reduced by 89.3%. 
Overall, glucocorticoids significantly reduced the incidence 
of positive MRAs (29 vs 3, p <0.005). 
ESR and CRP levels were significantly lower in glucocorti-
coid-treated patients (median ESR 18 vs 57 mm/h, p <0.05; 
median CRP 8.5 vs 26.5 mg/l, p <0.005). There was no valid 
cut-off of ESR/CRP values for diagnosis or exclusion of large-
vessel vasculitis, independent of glucocorticoid intake. 
Histology was positive during glucocorticoid application in 
six patients (five MRA negative and one MRA positive). 
Discussion 
The most striking finding was the vessel wall oedema in the 
vast majority of MRA-positive but in only two of the MRA-
negative patients. This is a recently published observation in 
temporal arteritis [10], active Takayasu arteritis [19] and 
thoracic aortitis [11], but has rarely been described in giant-
cell arteritis. The excellent interobserver agreement points 
to only few questionable cases that were resolvable after 
discussion and/or within the clinical context. In summary, 
MRA read by experienced radiologists is able to provide 
reliable results. 
We found a marked loss of valid MRA results after more 
than 5 days of glucocorticoid therapy, congruent with the 
reduced diagnostic accuracy of MRA in temporal arterial 
vasculitis [10]. Furthermore, Hauenstein et al. reported a 
marked loss of MRI sensitivity to 56% after more than 4 days 
of glucocorticoid treatment [20]. These findings contrast 
with the histology of temporal artery biopsies. As described 
earlier, cell infiltrates remain detectable for 2 to 4 weeks 
after the start of glucocorticoid therapy [21]. Collectively, 
these data suggest that MRA should be before the start of 
glucocorticoid treatment or very shortly thereafter. If results 
are clearly positive, additional temporal artery biopsy may 
be unnecessary. However, in negative MRA, biopsies are 
recommended. 
CRP values rapidly declined after glucocorticoid treatment 
initiation, and the decline correlated with the loss of in-
flammatory MRA signals. ESR/CRP could not predefine or 
exclude large-vessel vasculitis regardless of glucocorticoid 
intake. This is probably explained by the nonspecificity of 
the acute phase response. 
FDG-PET in suspected large-vessel vasculitis provided simi-
lar values of sensitivity and specificity [12]. In contrast to 
MRA, luminal and atherosclerotic changes are not detected 
by PET. As in our cohort, atherosclerotic and stenotic chang-
es on MRA represent a long-standing inflammatory process. 
This is worth detecting for future risk management. Addi-
tionally, PET scans are expensive, mostly require health-
insurance permission in advance and are available in large 
hospitals only. 
False positive results were rare, but 21% false negative MR 
angiograms warrant further explanation. In our study, most 
patients with negative MRA had glucocorticoid therapy of 
more than 5 days prior to MR investigation. Of the poly-
myalgia rheumatica patients with negative MRA, glucocorti-
coids had been prescribed for more than half (15 with gluco-
corticoids vs 7 without glucocorticoids). 
A recent study of 150 large-vessel vasculitis patients demon-
strated positive ACR criteria for giant cell arteritis in 39% 
only [1]. In our cohort, negative histology of temporal arteri-
al biopsies might have missed large-vessel vasculitis. It has 
been shown earlier that in cases of suspicion of large-vessel 
vasculitis and negative histology, thoracoabdominal arteries 
should be searched for vasculitis. 
Diagnostic algorithms are about to change. The two recent 
randomised controlled trials evaluating the efficacy of the 
biologic agent tocilizumab both included patients with signs 
and symptoms of giant cell arteritis, with positive histologi-
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cal findings in temporal artery specimens or positive find-
ings on MRA [22, 23]. 
Strengths and limitations 
Limitations of our study are the retrospective design, with 
missing data, and the fact that no predefined categorical 
characteristics of large-vessel vasculitis and/or indications 
for MRA were applied. Nevertheless, the long-standing 
experience of the consultant rheumatologists helped to 
correctly detect most of the ill patients, whether large-vessel 
vasculitis, indication to exclude polymyalgia rheumatica-
associated large-vessel vasculitis or other large vessel pa-
thologies. Regular evaluation of thoracic plus abdominal 
large vessels might have detected locations otherwise 
missed. Meanwhile, a more patient-friendly protocol al-
lowed for one-session thoracoabdominal MRAs instead of 
two investigations at different times. 
Our cohort represents the largest evaluated for large vessel 
vasculitis with a standardised, long-standing protocol with-
in the same institution, the same clinical investigators, and 
radiologists blinded to the diagnosis reading MRAs inde-
pendently. 
Conclusions 
Contrast-enhanced MRA reliably identifies large-vessel 
vasculitis and helps to discriminate it from other large 
vessel pathologies. In contrast to histology, vasculitic signals 
on MRA are very sensitive to glucocorticoids, suggesting 
that MRA should be performed prior to initiation of gluco-
corticoid treatment. 
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